PMTI: Umsatz + 133 % im Q2 !!!!!!! - 500 Beiträge pro Seite

[ajuga]

Palomar Medical (PMTI) hat den Umsatz im zweiten Quartal im Vergleich zum ersten Quartal um 133 % auf 6.1 Mio $ gesteigert. Der Verlust wurde auf nur noch 6 US-Cents pro Aktie reduziert.
Für die nächsten Quartale rechnet das Unternehmen mit weiter steigenden Umsätzen, so dass in Kürze der BreakEven erreicht werden wird.
Im dritten Quartal soll mit dem Vertrieb des neuen EsteLux(TM)-Lasers begonnen werden.

Die Aktie dürfte heute in New York einen kräftigen Anstieg verbuchen.
Vom Jahrestiefststand bei 0,75 $ Anfang April konnte die Aktie bereits auf bis zu 3 $ steigen. Mit dem gestrigen Schlusskurs von 2,7 $ errechnet sich eine Marktkapitalisierung von nicht einmal 30 Mio $.


ajuga
http://www.usmusterdepot.de/


Palomar Increases Revenues 133 Percent and Cuts Losses 85 Percent in
Second Quarter 2001

BURLINGTON, Mass., Jul 26, 2001 /PRNewswire via COMTEX/ -- Palomar Medical
Technologies, Inc. (Nasdaq: PMTI) today announced financial results for the
second quarter ended June 30, 2001. For the second quarter ended June 30, 2001,
revenues increased 133 percent to $6.1 million, compared with revenues of $2.6
million for the second quarter ended June 30, 2000. The increase in revenues is
due to a combination of ramp up in product sales and back-owed royalties. Net
loss for the second quarter ended June 30, 2001 was reduced by 85 percent to
$573,000, or $(0.06) per diluted share, as compared with net loss of $3.8
million, or $(0.38) per diluted share, excluding a non-recurring gain of $3.1
million, for the second quarter ended June 30, 2000. Gross profit increased
dramatically to $2.4 million, or 40 percent of revenues, for the second quarter
ended June 30, 2001, as compared to $32,000, or 1 percent of revenues for the
second quarter ended June 30, 2000. Gross profit as a percent of revenues has
been steadily increasing quarter to quarter over the past year as sales volume
continues to increase.

For the six months ended June 30, 2001, revenues increased 77 percent to $9.7
million, compared with revenues of $5.4 million for the six months ended June
30, 2000. Net loss for the six months ended June 30, 2001 was reduced by 66
percent to $2.5 million, or $(0.25) per diluted share, as compared with net loss
of $7.4 million, or $(0.74) per diluted share, excluding a non-recurring gain of
$3.1 million, for the six months ended June 30, 2000. Gross profit increased
dramatically to $3.3 million, or 35 percent of revenues, for the six months
ended June 30, 2001, as compared to $335,000, or 6 percent of revenues for the
six months ended June 30, 2000.

Louis P. (Dan) Valente, chairman and chief executive officer of Palomar,
commented: "The future of Palomar is brighter now than at any time in the
history of the company. At the end of the second quarter we started shipments of
the newly introduced Palomar Q-YAG 5(TM) laser system for tattoo and pigmented
lesion removal. We have also received a number of orders and plan to start
shipments of the Palomar EsteLux(TM) pulsed-light system for hair removal in the
next few weeks."

Valente added: "We could not be happier with the progress we have made during
this year. Our second quarter loss has been substantially reduced from the first
quarter, and we plan to continue this positive trend. We have also continued our
substantial commitment to the future and are investing heavily in research and
product development. The sales of the Palomar SLP1000(TM) have continued to ramp
up and we expect the recently introduced Q-YAG 5 and EsteLux to continue to
increase our revenues and gross profit over the next few quarters.

To get more information regarding Palomar and its products, please visit
Palomar`s web site at www.palmed.com. Also, to continue to receive the most
up-to-date information and latest news on Palomar as it happens, sign up to
receive automatic e-mail alerts by going to the e-mail alerts page in the
investor relations section of the web site.

Palomar is a leading researcher and developer of proprietary laser/light based
systems for hair removal and other cosmetic treatments and is the first company
to obtain clearance from the FDA for "permanent hair reduction." Palomar hair
removal systems have been installed in physician practices worldwide, and
hundreds of thousands of treatments have been performed. New and exciting
indications are being tested to further advance the hair removal market and
other cosmetic applications including fat reduction, acne treatment and skin
rejuvenation.

[ajuga]

Kleiner Fehler:
Die 133 %-Steigerung bezieht sich nicht auf das erste Quartal (wie oben gepostet) sondern auf das entsprechende Vorjahresquartal.
Gegenüber dem ersten Quartal stieg der Umsatz aber immerhin auch um fast 70 % !!


ajuga